Bizzell Senior Associate Featured in JAMDA Article

Bizzell Senior Associate Featured in JAMDA Article

Mark Stewart, MPH, Senior Associate of Health Systems and Services, is an author on an in-press manuscript in The Journal of the Post-Acute and Long-Term Care Medicine (JAMDA). The article details a consensus-based definition for omissions of care in nursing homes that lead to increased risk for harm or adverse outcomes, decreased quality of life for residents, and increased healthcare expenditures. This definition is clear, meaningful, and actionable for nursing homes. Providers and researchers applying this definition can improve harm prevention and increase consistency in research methods.

Mark has more than 20 years of experience leading health innovation projects focused on ensuring the quality of care and improving outcomes. At Bizzell, he provides critical support to the organization managing, advising, and operationalizing projects advancing health systems and services improvements in areas such including person and family-centered care, shared decision making, patient-reported outcomes, healthcare disparities, and quality improvement. In addition, Mark serves as the Program Manager for the Centers for Medicare and Medicaid Services (CMS) Data Validation and Administrative (DVA) contract.

JAMDA is the leading peer-reviewed publication for practical information and research directly applicable to healthcare professionals providing post-acute and long-term care (PA/LTC), as well as policymakers, organizational leaders, educators, and advocates.

Read Article: https://www.jamda.com/article/S1525-8610(20)30706-4/fulltext

Preserving the Mental Wellness of Our Healthcare Heroes

Preserving the Mental Wellness of Our Healthcare Heroes

Dr. Anton C. Bizzell underscores in Psychology Today how The Bizzell Group (Bizzell) helps preserve the mental wellness of our healthcare heroes. People often choose a career in medicine because they desire to help, heal, and make a difference. They have the drive to fulfill these responsibilities, and their accomplishments are often groundbreaking. “We can never forget that these healthcare workers are human beings, not robots,” Dr. Bizzell writes. “As this pandemic stretches toward a second year, we cannot expect them to continue to do their jobs well without better support for their mental well-being.” Organizations—including Bizzell—are beginning to step up at the national, state, and local levels to help these everyday heroes.

READ MORE: Preserving the Mental Wellness of Our Healthcare Heroes

Addressing the Signs of Mental Health Decline in the Workplace

Addressing the Signs of Mental Health Decline in the Workplace

In a recent U.S. Chamber of Commerce Foundation (USCCF) blog post, “How Forward-Looking Companies Can Address the Signs of Mental Health Decline in the Workplace,” Dr. Anton C. Bizzell discusses how business leaders can learn the signs of mental health disorders in the workplace and shares strategies employers can implement to boost company morale. As a small business owner and advisory board member for the U.S. Chamber of Commerce Foundation, Dr. Bizzell has witnessed first-hand how negative repercussions due to an unfavorable environment could impact employees’ mental health.
The initial step for any business owner looking to address mental health in their workplace is to learn the signs of decline in mental health before it has a much larger domino effect. If an employee’s mental health is altered due to discouragement at work, there are strategies employers can implement to help manage mental health decline and boost company morale, Dr. Bizzell writes.

READ MORE: U.S. Chamber of Commerce Foundation (USCCF)

Dr. Bizzell Speaks About the First FDA-Approved Treatment for Ebola

Dr. Bizzell Speaks About the First FDA-Approved Treatment for Ebola

Dr. Anton C. Bizzell shares his insights in the Verywell Health article, “Regeneron Earns First-Ever FDA Approval For Ebola Treatment,” about the U.S. Food and Drug Administration (FDA) approval of Inmazeb, an antibody cocktail designed to treat the Ebola virus. A mixture of three monoclonal antibodies administered via injection is the first FDA-approved treatment for the virus. The drug is manufactured by Regeneron, the same company behind the antibody cocktail aimed at treating COVID-19. The Bizzell Group (Bizzell) has been on the ground fighting the Ebola virus in the Democratic Republic of Congo. “The approval of Inmazeb is not only a big deal, it is the approach to prevent a future Ebola pandemic worldwide,” Dr. Bizzell tells Verywell.

READ MORE: Regeneron Earns First-Ever FDA Approval For Ebola Treatment